UA88440C2 - ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β - Google Patents

ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β

Info

Publication number
UA88440C2
UA88440C2 UAA200501449A UA2005001449A UA88440C2 UA 88440 C2 UA88440 C2 UA 88440C2 UA A200501449 A UAA200501449 A UA A200501449A UA 2005001449 A UA2005001449 A UA 2005001449A UA 88440 C2 UA88440 C2 UA 88440C2
Authority
UA
Ukraine
Prior art keywords
glomerulonephritis
renal failure
chronic renal
interferon
therapies
Prior art date
Application number
UAA200501449A
Other languages
English (en)
Ukrainian (uk)
Inventor
Рой Р. Лобб
Original Assignee
Байоджен Айдек Ма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Айдек Ма Инк. filed Critical Байоджен Айдек Ма Инк.
Publication of UA88440C2 publication Critical patent/UA88440C2/ru

Links

Classifications

    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L47/00—Traffic control in data switching networks
    • H04L47/50—Queue scheduling
    • H04L47/62—Queue scheduling characterised by scheduling criteria
    • H04L47/6285—Provisions for avoiding starvation of low priority queues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L47/00—Traffic control in data switching networks
    • H04L47/10—Flow control; Congestion control
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L47/00—Traffic control in data switching networks
    • H04L47/10—Flow control; Congestion control
    • H04L47/215—Flow control; Congestion control using token-bucket
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W28/00—Network traffic management; Network resource management
    • H04W28/02—Traffic management, e.g. flow control or congestion control
    • H04W28/0252—Traffic management, e.g. flow control or congestion control per individual bearer or channel
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W28/00—Network traffic management; Network resource management
    • H04W28/02—Traffic management, e.g. flow control or congestion control
    • H04W28/0278—Traffic management, e.g. flow control or congestion control using buffer status reports
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W72/00—Local resource management
    • H04W72/20—Control channels or signalling for resource management
    • H04W72/23—Control channels or signalling for resource management in the downlink direction of a wireless link, i.e. towards a terminal
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W8/00—Network data management
    • H04W8/02—Processing of mobility data, e.g. registration information at HLR [Home Location Register] or VLR [Visitor Location Register]; Transfer of mobility data, e.g. between HLR, VLR or external networks
    • H04W8/04—Registration at HLR or HSS [Home Subscriber Server]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W72/00—Local resource management
    • H04W72/12—Wireless traffic scheduling

Abstract

В данном изобретении предлагаются способы лечения и фармацевтические агенты для применения в лечении млекопитающих субъектов, которые имеют гломерулонефрит или хроническую почечную недостаточность, или риск их развития. Способы включают введение терапевтических агентов, которые содержат ИФН-.
UAA200501449A 2002-07-17 2003-07-17 ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β UA88440C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39639302P 2002-07-17 2002-07-17

Publications (1)

Publication Number Publication Date
UA88440C2 true UA88440C2 (ru) 2009-10-26

Family

ID=30116023

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200501449A UA88440C2 (ru) 2002-07-17 2003-07-17 ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β

Country Status (20)

Country Link
US (1) US20070025965A1 (ru)
EP (1) EP1553971A4 (ru)
JP (2) JP4883665B2 (ru)
KR (2) KR20050021502A (ru)
CN (2) CN1681527A (ru)
AU (1) AU2003256603C1 (ru)
BR (1) BR0312947A (ru)
CA (1) CA2492649A1 (ru)
EA (1) EA009938B1 (ru)
GE (1) GEP20084499B (ru)
IL (2) IL166256A (ru)
IS (1) IS7650A (ru)
MX (1) MXPA05000658A (ru)
NO (1) NO20050827L (ru)
NZ (1) NZ538217A (ru)
PL (1) PL374914A1 (ru)
RS (1) RS20050035A (ru)
UA (1) UA88440C2 (ru)
WO (1) WO2004006756A2 (ru)
ZA (1) ZA200500342B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1811991B1 (en) 2004-11-10 2018-11-07 Genzyme Corporation Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis
RS57549B1 (sr) 2005-08-26 2018-10-31 Ares Trading Sa Proces za pripremu glikoziliranog interferona beta
JP5199112B2 (ja) 2005-12-09 2013-05-15 アレス トレーディング ソシエテ アノニム Ｆｓｈ又はｆｓｈ変異体を精製するための方法
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
WO2007092252A2 (en) * 2006-02-03 2007-08-16 Modigene Inc Long-acting polypeptides and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
KR101532369B1 (ko) * 2006-12-11 2015-06-29 삼성전자주식회사 휴대용 단말기의 원격제어 장치 및 방법
EP2594562B1 (en) 2007-05-31 2016-07-20 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
CN101888840A (zh) 2007-10-05 2010-11-17 简詹姆公司 使用脑酰胺衍生物治疗多囊性肾疾病的方法
JP2011500756A (ja) * 2007-10-22 2011-01-06 メルク セローノ ソシエテ アノニム Ｆｃ融合タンパク質を精製する方法
WO2009055458A1 (en) * 2007-10-27 2009-04-30 Research In Motion Limited Content disposition system and method for processing message content in a distributed environment
ATE555812T1 (de) * 2007-12-20 2012-05-15 Merck Serono Sa Peg-interferon-beta-formulierungen
CA2731685A1 (en) * 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
RU2578947C2 (ru) 2008-10-03 2016-03-27 Джензайм Корпорейшн Ингибиторы глюкозилцерамидсинтазы 2-ациламинопропанольного типа
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
JP2014506889A (ja) * 2011-02-18 2014-03-20 ステムディーアール インク． Ｓｉｒｔ１発現誘導物質を含む敗血症または敗血症性ショックの予防または治療用組成物
JP2015520128A (ja) 2012-04-19 2015-07-16 オプコ バイオロジクス リミテッド 長時間作用性オキシントモジュリン変異体とその作製方法
BR122020018510B1 (pt) 2012-11-20 2023-03-14 Opko Biologics Ltd Método para aumentar incrementalmente o tamanho hidrodinâmico de um fator de coagulação ativado viia
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3988113A1 (en) 2015-06-19 2022-04-27 OPKO Biologics Ltd. Long-acting coagulation factors and methods of producing same
FI126979B (en) 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and use thereof
RU2728696C2 (ru) * 2018-12-28 2020-07-30 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Моноклональное антитело к интерферону бета-1а человека

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0797998A4 (en) * 1995-11-17 2003-01-15 Toray Industries PROTECTION FOR ENDOTHEL CELLS
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
CA2343094A1 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
JP2004536819A (ja) * 2001-06-11 2004-12-09 トランジション・セラピューティックス・インコーポレーテッド ウイルス性、増殖性および炎症性の疾患の治療のためにビタミンｂ１２および治療薬を用いた複合治療

Also Published As

Publication number Publication date
EP1553971A2 (en) 2005-07-20
AU2003256603B2 (en) 2009-07-30
PL374914A1 (en) 2005-11-14
JP2005537269A (ja) 2005-12-08
NZ538217A (en) 2007-04-27
AU2003256603C1 (en) 2010-07-15
IL166256A (en) 2010-11-30
JP4883665B2 (ja) 2012-02-22
EA009938B1 (ru) 2008-04-28
IL200892A0 (en) 2010-05-17
CA2492649A1 (en) 2004-01-22
AU2003256603A1 (en) 2004-02-02
KR20050021502A (ko) 2005-03-07
WO2004006756A3 (en) 2004-08-19
EA200500218A1 (ru) 2006-08-25
KR20110053390A (ko) 2011-05-20
US20070025965A1 (en) 2007-02-01
IL166256A0 (en) 2006-01-15
WO2004006756A2 (en) 2004-01-22
CN101664545A (zh) 2010-03-10
MXPA05000658A (es) 2005-08-19
BR0312947A (pt) 2007-07-10
EP1553971A4 (en) 2006-07-05
ZA200500342B (en) 2006-07-26
IS7650A (is) 2005-01-14
JP2011144204A (ja) 2011-07-28
GEP20084499B (en) 2008-10-10
CN1681527A (zh) 2005-10-12
NO20050827L (no) 2005-04-15
IL200892A (en) 2014-11-30
RS20050035A (en) 2007-06-04

Similar Documents

Publication Publication Date Title
UA88440C2 (ru) ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β
PL371736A1 (en) Method for administering glp-1 molecules
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
FR13C0062I2 (fr) Compositions pharmaceutiques comprenant du dextromethorphan et de la quinidine pour traiter des troubles neurologiques
SG147442A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
MY180762A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
MXPA04006572A (es) Terapia de combinacion antivirica.
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
TW200531679A (en) Methods of modulating cytokine activity; related reagents
MXPA03007140A (es) Derivados de carbolina.
NO20052059L (no) Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta.
MY137620A (en) Therapeutic treatment
TW200509896A (en) Analeptic and drug combinations
CY1105117T1 (el) Θepαπειες για τη χρονια νεφρικη ανεπαρκεια χρησιμοποιωντας ανταγωνιστες των ενσωματινων
ATE422905T1 (de) Verbandsmaterial mit wirkstoffen
EA200500774A1 (ru) Новая синергетическая комбинация, включающая рофлумиласт и формотерол
ATE395936T1 (de) Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten
MY140194A (en) Novel fusidic acid derivatives
NZ514691A (en) Method to type prion proteins
NO20045344L (no) Kombinasjon for behandling av luftveisforstyrrelser
UA70188A (en) Method for treating chronic heart insufficiency
AR103941A2 (es) Terapia de combinación para tratamiento de desórdenes neovasculares oculares
TW200510447A (en) Novel fusidic acid derivatives
WO2005011589A3 (en) Drug delivery methods and devices
UA70017A (en) Method for conservative treatment of chronic tonsillitis in adults